ID
13750
Description
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure; ODM derived from: https://clinicaltrials.gov/show/NCT01133886
Link
https://clinicaltrials.gov/show/NCT01133886
Keywords
Versions (1)
- 3/2/16 3/2/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
March 2, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Acute Myeloid Leukemia NCT01133886
Eligibility Acute Myeloid Leukemia NCT01133886
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
1. nursing and pregnant females.
Data type
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Description
2. females of childbearing potential and males not willing to practice an effective method of contraception whilst receiving decitabine and for 2 months after the last infusion.
Data type
boolean
Alias
- UMLS CUI [1]
- C3831118
- UMLS CUI [2]
- C0700589
Description
3. patients with previous malignancy or concurrent malignancy.
Data type
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
4. uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure and unstable angina pectoris.
Data type
boolean
Alias
- UMLS CUI [1]
- C0009488
Description
5. ongoing oral corticosteroids are not permitted. however, use of corticosteroids (topical and inhaled) is permitted and prophylactic steroids are allowed for transfusion reactions.
Data type
boolean
Alias
- UMLS CUI [1]
- C0001617
Description
6. patients who have received any investigational agent within the 30 days preceding the first dose of study drug.
Data type
boolean
Alias
- UMLS CUI [1]
- C1875319
Description
7. patients who have received prior intensive combination chemotherapy or high-dose cytarabine (>/= 1g/m*2 per dose). (prior biologic therapies, targeted therapies and single agent chemotherapy are allowed).
Data type
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0010711
Description
8. patients who have an active viral or bacterial infection. note: no patient is allowed to enter the study unless infections have been fully treated and the patient has remained afebrile for 7 days without antibiotics.
Data type
boolean
Alias
- UMLS CUI [1]
- C0009450
Description
9. patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia.
Data type
boolean
Alias
- UMLS CUI [1]
- C0002880
- UMLS CUI [2]
- C0272286
Description
10. patients who have previously been treated with decitabine.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0049065
- UMLS CUI [1,2]
- C1514463
Description
11. patients who have known positive serology for hiv.
Data type
boolean
Alias
- UMLS CUI [1]
- C0019682
Description
12. patients with a condition that may be unable to comply with the treatment and monitoring requirements of the study.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Similar models
Eligibility Acute Myeloid Leukemia NCT01133886
- StudyEvent: Eligibility
C0023480 (UMLS CUI [2])
C0023467 (UMLS CUI [3])
C1982687 (UMLS CUI [4])
C0438286 (UMLS CUI [1,2])
C0201899 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
C0010711 (UMLS CUI [2])
C0272286 (UMLS CUI [2])
C1514463 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])